Permeability of PEGylated immunoarsonoliposomes through in vitro blood brain barrier-medulloblastoma co-culture models for brain tumor therapy

Pharmaceutical Research

Volumn 32, Issue 3, 2015, Pages 1072-1083

  Al Shehri, Abdulghani ^a   Favretto, Marco E ^b   Ioannou, Panayiotis V ^c   Romero, Ignacio A ^d   Couraud, Pierre Olivier ^e   Weksler, Babette Barbash ^f   Parker, Terry L ^a   Kallinteri, Paraskevi ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

^c UNIVERSITY OF PATRAS   (Greece)

^d OPEN UNIVERSITY   (United Kingdom)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

arsonolipids; blood brain barrier cancer model; cell aggregates; hCMEC D3 cells; transferrin receptors

Indexed keywords

CD71 ANTIGEN; DEXTRAN; IMMUNOARSONOLIPOSOME; IMMUNOLIPOSOME; NANOCARRIER; PROTEIN ZO1; RECEPTOR ANTIBODY; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; ANTIBODY; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; LIPOSOME; MACROGOL DERIVATIVE; ORGANOARSENIC DERIVATIVE;

ANTIBODY COMBINING SITE; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; COCULTURE; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; FILTERS AND MEMBRANES; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMORTALIZED CELL LINE; IN VITRO STUDY; MEDULLOBLASTOMA; MEDULLOBLASTOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; CAPILLARY PERMEABILITY; CELL SURVIVAL; CEREBELLUM TUMOR; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; ENDOTHELIUM CELL; IMMUNOLOGY; MEDICINAL CHEMISTRY; METABOLISM; PATHOLOGY; PHARMACEUTICS; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE; VALIDATION STUDY;

ANTIBODIES; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; CELL SURVIVAL; CEREBELLAR NEOPLASMS; CHEMISTRY, PHARMACEUTICAL; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; HUMANS; IMMUNOCONJUGATES; LIPOSOMES; MEDULLOBLASTOMA; POLYETHYLENE GLYCOLS; RECEPTORS, TRANSFERRIN; TECHNOLOGY, PHARMACEUTICAL;

EID: 84925504064     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1519-8     Document Type: Article

References (35)

1. Pardridge WM. Drug targeting to the brain. Pharm Res. 2007;24(9):1733-44.
2. Cucullo L, Aumayr B, Rapp E, Janigro D. Drug delivery and in vitro models of the blood-brain barrier. Curr Opin Drug Discov Devel. 2005;8(1):89-99.
3. Prudhomme JG, Sherman IW, Land KM, Moses AV, Stenglein S, Nelson JA. Studies of Plasmodium falciparum cytoadherence using immortalized human brain capillary endothelial cells. Int J Parasitol. 1996;26(6):647-55.
4. Ketabi-Kiyanvash N, Herold-Mende C, Kashfi F, Caldeira S, Tommasino M, Haefeli WE, et al. NKIM-6, a new immortalized human brain capillary endothelial cell line with conserved endothelial characteristics. Cell Tissue Res. 2007;328(1):19-29.
5. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005;19(13):1872-4.
6. Poller B, Gutmann H, Krahenbuhl S, Weksler B, Romero I, Couraud PO, et al. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J Neurochem. 2008;107(5):1358-68.
7. Cucullo L, Couraud PO, Weksler B, Romero IA, Hossain M, Rapp E, et al. Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studies. J Cereb Blood Flow Metab. 2008;28(2):312-28.
8. Boado RJ, Pardridge WM. The Trojan horse liposome technology for nonviral gene transfer across the blood-brain barrier. J Drug Deliv. 2011;2011:296151.
9. Huynh GH, Deen DF, Szoka FC. Barriers to carrier mediated drug and gene delivery to brain tumors. J Control Release. 2006;110(2):236-59.
10. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1-2):271-84.
11. Evens AM, Tallman MS, Gartenhaus RB. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res. 2004;28(9):891-900.
12. Kallinteri P, Fatouros D, Klepetsanis P, Antimisiaris SG. Arsenic trioxide liposomes: encapsulation efficiency and in vitro stability. J Liposome Res. 2004;14(1-2):27-38.
13. Gortzi O, Papadimitriou E, Kontoyannis CG, Antimisiaris SG, Ioannou PV. Arsonoliposomes, a novel class of arsenic-containing liposomes: effect of palmitoyl-arsonoli pid-containing liposomes on the viability of cancer and normal cells in culture. Pharm Res. 2002;19(1):79-86.
14. Favretto ME, Marouf S, Ioannou P, Antimisiaris SG, Parker TL, Kallinteri P. Arsonoliposomes for the potential treatment of medulloblastoma. Pharm Res. 2009;26(10):2237-46.
15. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, Dehouck MP, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov. 2007;6(8):650-61.
16. Grabarek Z, Gergely J. Zero-length crosslinking procedure with the use of active esters. Anal Biochem. 1990;185:131-5.
17. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.
18. Stewart JC. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem. 1980;104(1):10-4.
19. Koda Y, Shiotani K, Toth I, Tsuda Y, Okada Y, Blanchfield JT. Comparison of the in vitro apparent permeability and stability of opioid mimetic compounds with that of the native peptide. Bioorg Med Chem Lett. 2007;17(7):2043-6.
20. Cecchelli R, Dehouck B, Descamps L, Fenarta L, Buée-Scherrera V, Duhem C, et al. In vitro model for evaluating drug transport across the blood-brain barrier. Adv Drug Deliv Rev. 1999;36:165-78.
21. Underwood JL, Murphy CG, Chen J, Franse-Carman L, Wood I, Epstein DL, et al. Glucocorticoids regulate transendothelial fluid flow resistance and formation of intercellular junctions. Am J Physiol. 1999;277(2 Pt 1):C330-42.
22. Choi JJ, Wang S, Tung YS, Morrison 3rd B, Konofagou EE. Molecules of various pharmacologically-relevant sizes can cross the ultrasound-induced blood-brain barrier opening in vivo. Ultrasound Med Biol. 2010;36:58-67.
23. Ortiz-Zapater E, Soriano-Ortega E, Marcote MJ, Ortiz-Masiá D, Aniento F. Trafficking of the human transferrin receptor in plant cells: effects of tyrphostin A23 and brefeldin A. Plant J. 2006;48(5):757-70.
24. Wen DY, Hall WA, Conrad J, Godal A, Flørenes VA, Fodstad O. In vitro and in vivo variation in transferrin receptor expression on a human medulloblastoma cell line. Neurosurgery. 1995;36(6):1158-63. discussion 1163-4.
25. Torchilin V, Weissig, V. Liposomes 2nd ed., A practical approach. Oxford University Press; 2003.
26. Furuse M, Itoh M, Hirase T, Nagafuchi A, Yonemura S, Tsukita S. Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J Cell Biol. 1994;127:1617-26.
27. Förster C, Burek M, Romero IA, Weksler B, Couraud PO, Drenckhahn D. Differential effects of hydrocortisone and TNFα on tight junction proteins in an in vitro model of the human blood-brain barrier. J Physiol. 2008;586:1937-49.
28. Kusch-Poddar M, Drewe J, Fux I, Gutmann H. Evaluation of the immortalized human brain capillary endothelial cell line BB19 as a human cell culture model for the blood-brain barrier. Brain Res. 2005;1064:21-31.
29. Rist RJ, Romero IA, Chan MWK, Couraud PO, Roux F, Abbott NJ. F-Actin cytoskeleton and sucrose permeability of immortalised rat brain microvascular endothelial cell monolayers: effects of cyclic AMP and astrocytic factors. Brain Res. 1997;768:10-8.
30. Regina A, Romero IA, Greenwood J, Adamson P, Bourre JM, Couraud PO, et al. Dexamethasone regulation of P-glycoprotein activity in an immortalized rat brain endothelial cell line, GPNT. J Neurochem. 1999;73:1954-63.
31. Deri MA, Abraham CS, Kataoka Y, Niwa M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol. 2005;25:59-127.
32. Hayashi K, Nakao S, Nakaoke R, Nakagawa S, Kitagawa N, Niwa M. Effects of hypoxia on endothelial/pericytic co-culture model of the blood-brain barrier. Regul Pept. 2004;123:77-83.
33. Furie MB, Naprstek BL, Silverstein SC. Migration of neutrophils across monolayers of cultured microvascular endothelial cells. An in vitro model of leucocyte extravasation. J Cell Sci. 1987;88:161-75.
34. Mayhan WG. VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP dependent pathway. Am J Physiol. 1999;276(5 Pt 1):C1148-53.
35. Prat A, Biernacki K, Wosik K, Antel JP. Glial cell influence on the human blood-brain barrier. Glia. 2001;36(2):145-55.